About Strand Life Sciences Pvt Ltd in 5th Floor, Kirloskar Business Park, Bellary Road, Hebbal, Bangalore

Strand's entry into healthcare was through software products and services that combine advanced visualization, systems modeling, and scientific insights for enabling biological and health sciences research. Over 2000 research labs worldwide (about 30% of global market share) and 50 hospitals have adopted Strand's genomics solutions today. These include leading clinical research, pharmaceutical and biotechnology organizations. With a highly skilled interdisciplinary workforce of more than 200 computer and life scientists, Strand has set up three clinical and translational research laboratories in Bangalore that are enabled with cutting-edge Next Generation Sequencing (NGS) technologies. Strand is a portfolio company of Biomark Capital Partners, a San Francisco based global fund for health and life sciences. By enabling DNA sequence-based diagnostics and clinical genomic data interpretation using a strong foundation of computational, scientific, and medical expertise, Strand is bringing personalized medicine to the world. For more information, please visit www.strandls.com

Milestones
2015
• Launched pan-cancer genomic profiling service in the US, powered by a state-of-the-art, CLIA certified lab at Colorado, USA in March 2015.
• Partnered with organisations across the globe to further the application of next-generation sequencing in research and diagnostics:
o March 2015: Announced partnership with MRI Global to set up reference laboratory in India to co-develop infectious disease diagnostics
oJune 2015: Announced cooperation with TATAA Biocenter, Sweden to distribute Strand NGS in Europe and offer NGS courses using Strand NGS
oJune 2015: Announced partnership with ReadSense, a Moscow-based genomics company to jointly develop affordable NGS-based diagnostic tests for neurological and primary immunodeficiency disorders
• Established contemporary genomics center offering genomics-based cancer diagnostics and genetic counselling services in hospitals across India
2014
• Received funding from Biomark Capital — a venture capital and private equity firm in healthcare and life sciences with its offices set in Moscow, San Francisco and Greenwich (USA)
• Received US patent protection in February 2014 for Virtual Liver model to predict htoxicity in rat and human liver (USPTO patent no. 8,645,075)
• Recognised by CIO Review as one of the 20 most promising tech solution providers to the Pharma and Life Science industries 2014
• Became a Member of 'Global Alliance for Genomics and Health'
• Announced collaborations with Triesta Sciences, a unit of HealthCare Global (HCG)and Sapien Biosciences for providing genetic based diagnostics services in HCG and Apollo hospitals across India